DGAP-Adhoc: SYGNIS Pharma AG: SYGNIS Pharma AG secures further financial resources with new investors loan

SYGNIS Pharma AG / Key word(s): Corporate Action

08.07.2013 15:00

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc-Release according to § 15 WpHG

SYGNIS Pharma AG secures further financial resources with new investors
loan

Heidelberg, 8 July 2013 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03, Prime Standard) today reports on the granting of a loan for a
total amount of up to EUR 0.55 million by a group of international
investors comprising the Bedford Investment Fund, George Town, Cayman
Islands, The Excalibur Investments Fund, George Town, Cayman Islands and
Casticapital, S.L., Las Palmas de Gran Canaria, Spain, as well as Mr.
Gonzalo Rodríguez-Fraile Díaz, who is a member of the Supervisory Board of
SYGNIS Pharma AG. Another member of the Supervisory Board of SYGNIS Pharma
AG, Mr. Pedro-Agustín del Castillo Machado, is Chairman of the Board of
Directors of Casticapital, S.L.

The loan bears interest at customary market conditions. The loan, which is
payable on demand, secures the financing of SYGNIS' existing operations,
according to the present plans, until mid September 2013. The loan is
secured and is due for repayment not before the end of 2014.

Under the loan agreement, the international investors may, subject to
certain conditions, participate in a possible future capital increase of
SYGNIS by subscribing for newly issued SYGNIS shares from the Company's
authorized capital.

**** end of ad hoc ****

For further information please contact:

SYGNIS Pharma AG
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta@sygnis.es

### Disclaimer
This publication is intended for information only and constitutes neither
an offer to sell nor an invitation to buy securities. Some statements
included in this press release, relating neither to proven financial
results nor other historical data, should be viewed as forward-looking,
i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered
to be total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and goals of
SYGNIS Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not undertake
to publicly update or revise these statements in the light of new
information or future results or for any other reason.
###

---------------------------------------------------------------------------

Language: English
Company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
69120 Heidelberg
Germany
Phone: 06221 454-6
Fax: 06221 454-700
E-mail: contact@sygnis.de
Internet: www.sygnis.de
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, München, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------